Introgen Therapeutics, Inc. (INGN) Tops Q2 EPS by 4c, Raises Guidance

Introgen Therapeutics, Inc. (NASDAQ: INGN) reported Q2 EPS of $0.11, $0.04 better than the analyst estimate of $0.07. Revenue for the quarter came in at $30.4 million versus the consensus estimate of $23.93 million.

Introgen Therapeutics, Inc. sees FY2014 revenue of $102-106 million, versus the consensus of $95.80 million. This compares to the previous revenue expectation of $92.0 to $96.0 million which was provided on May 13, 2014.

Adjusted EBITDA is projected to be in the range of $19.0 to $20.5 million which is updated from the previous range of $18.0 to $19.5 million. We expect to invest in additional sales and marketing resources in the second half of 2014 associated both with the launch of the Inogen At Home™ product and also to continue to scale our sales infrastructure to drive future revenues.

Net income is projected to be in the range of $4.5 to $5.5 million, which is updated from the previous guidance of $4.0 to $5.0 millio

For earnings history and earnings-related data on Introgen Therapeutics, Inc. (INGN) click here.

You May Also Be Interested In

• Ennis (EBF) Reports In-Line Q1 EPS
• Benchmark Starts Boyd Gaming (BYD) at Buy
• Robinhood plans $2B convertible notes offering due 2029